Shaw said Biocon’s growth trajectory over the next five years will be “very exciting,” with even larger opportunities emerging beyond 2030 as big-ticket biologics go off patent.
Multiple factors contribute to rising obesity rates. However, excess caloric intake remains the primary driver. This conclusion is supported by multiple lines of evidence, including observational ...
Regeneron announced the FDA’s approval of two indications of Eylea HD, including an 8mg injection for patients with macular ...
Biocon is entering a transformative phase, leveraging regulatory shifts in the US and a strong insulin and GLP-1 portfolio to ...
FDA grants accelerated approval to Bayer's Hyrnuo and full approval to Amgen's Imdelltra, expanding treatment options for ...
The ProShares UltraPro Dow30 offers 3x daily leveraged exposure to the Dow Jones Industrial Average, appealing to active ...
A $100,000 factor-weighted model portfolio yields about 4%, with several stocks trading near decade-high dividend yields.
Major indices were in the green early on Thursday as investors cheered better than expected quarterly earnings from artificial intelligence darling Nvidia and digested September's long-delayed nonfarm ...
US biotech major Amgen’s Imdelltra (tarlatamab-dlle) received full approval from the us Food and Drug Administration (FDA) on ...
The company on Thursday, Nov. 20, announced that Olivier Leonetti, its executive vice president and CFO, will leave Eaton on ...
Accord BioPharma, Inc., the specialty division of Intas Pharmaceuticals, Ltd., focused on development of oncology, immunology ...
F or Big Pharma, the triumph of developing a new lifesaving blockbuster drug that generates billions in revenue is inevitably ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback